Peptide Vendors Shut Down: The 2026 Graveyard and the Red Flags That Showed Up First

Every peptide vendor that collapsed between late 2024 and mid-2026 broadcast the same four signals before it went down, and all four were checkable by a customer with a browser. The documented record is narrower than the rumor mill suggests: one federal criminal case with guilty pleas (Paradigm Peptides, N.D. Indiana, December 2025), a steadily growing stack of FDA warning letters running from Prime Peptides and Summit Research in December 2024 through Wholesale Peptide in June 2026, and a handful of voluntary closures that were never publicly explained at all. Strip out the speculation and the pattern that remains is unglamorous: no third-party identity testing you could verify at the lab, human-use marketing sitting on top of a “research use only” disclaimer, product names that changed while the claims did not, and a payment page that quietly stopped taking cards. The deciding check is the first one. If you cannot pull up a vendor’s certificate of analysis on the testing laboratory’s own website using an accession number, you are not buying a tested product - you are buying a PDF.

Published 2026 - For research use only (RUO). Nothing here is medical advice, a dosing protocol, or a human-use recommendation.

In a hurry? Jump to how Pepora scores on the checklist →

---

What is actually documented: closures and enforcement are not the same thing

Most “vendor graveyard” lists circulating online are unsourced. Below is only what a public government document supports. Anything a reader cannot pull up themselves has been left out.

Date	Vendor / entity	What is documented	Primary record
Dec 10, 2024	Prime Vitality Inc. dba Prime Peptides	FDA warning letter, unapproved new drugs (GLP-class compounds)	MARCS-CMS 695156
Dec 10, 2024	Summit Research Peptides	FDA warning letter, unapproved new drugs (multiple GLP-class and amylin-class compounds)	MARCS-CMS 695607
Feb 26, 2025	USApeptide.com	FDA warning letter, misbranded and unapproved new drugs	MARCS-CMS 696885
Sept 8, 2025	PureRawz	FDA warning letter, unapproved new drugs (tianeptine product line)	MARCS-CMS 715218
Sept 2025	50+ compounders, outsourcing facilities and online sellers	Coordinated FDA warning-letter wave; false “same as the approved drug” claims, cGMP and adverse-event reporting failures	FDA warning letter database
Dec 10, 2025	Paradigm Peptides / Paradigm R.E. LLC	Guilty pleas by owner Matthew Kawa and Jennifer Stechkober; products sold as SARMs contained testosterone	US v. Kawa et al., 3:25-cr-00091 (N.D. Ind.)
Dec 12, 2025	Pinnacle Professional Research dba Pinnacle Peptides	FDA warning letter, SARM products as unapproved new drugs	MARCS-CMS 719337
Mar 3, 2026	30 telehealth companies	FDA warning letters over compounded GLP-class marketing	FDA press announcement
Mar 31, 2026	Pink Pony Peptides (Lovega LLC), Mile High Compounds, Prime Sciences, Gram Peptides, PekCura Labs, plus two eBay stores (FormPour, and Guangzhou Huli Technology Co., Ltd. dba Fantasy Face)	Seven sellers cited in one batch, five research-chemical sites and two eBay stores, posted April 7, 2026	MARCS-CMS 721088, 721600, 721805, 721806, 721709, 722215, 722228
Jun 17, 2026	Wholesale Peptide	FDA warning letter	MARCS-CMS 729447

Two large closures sit deliberately outside that table. Peptide Sciences posted a voluntary shutdown notice in March 2026 with no stated reason, and no FDA or DOJ document naming it has surfaced publicly - the cause is unconfirmed, however confidently it is asserted elsewhere. Amino Asylum went dark in mid-2025 amid unverified community reports of a federal action, but the specifics circulating online are frequently contaminated: several high-ranking pages attribute the Kawa and Stechkober guilty pleas to Amino Asylum, when those defendants are Paradigm Peptides per DOJ’s own filings. If you see that conflation on a page, treat everything else on it as unverified. We cover the practical aftermath of both closures separately in the Amino Asylum alternatives breakdown, the Peptide Sciences follow-up, and the Science.bio post-mortem.

Four signals that were visible before each collapse

1. Testing that could not be verified anywhere except the vendor’s own site

This is the signal with the most direct evidence behind it. The single best published measurement of what actually ships in this market is still the JAMA analysis by Van Wagoner and colleagues, which chemically analysed 44 products marketed as SARMs and sold via the internet. The results:

Finding	Share of the 44 products
Contained any SARM at all	52%
Contained a different unapproved drug	39%
Contained substances not listed on the label	25%
Amount differed substantially from the label	59%
No active ingredient detected at all	9%

Those are 2017 numbers for SARMs, not 2026 numbers for peptides, and the article should not be read as measuring today’s peptide market. What it does establish, durably, is the structural point: in a market with no pre-market testing requirement, the label is an assertion, not a measurement. Paradigm’s case is the same failure with a criminal outcome attached - products advertised and labeled as SARMs contained testosterone, which is a controlled substance.

The operational check is narrow. Does the vendor name an actual laboratory, and can you find the report on that laboratory’s site rather than the vendor’s? Janoshik publishes reports with a unique key that resolve at public.janoshik.com; Freedom Diagnostics supports accession lookup at its own domain. A hosted PDF with a logo on it proves nothing at all, and the four fake-COA archetypes are well documented: a genuine report belonging to a different client, a fabricated report with no task number, a real report that is two years stale, and the promise to email documentation after payment. Our full walkthrough is in how to read a peptide COA and how to verify a COA by lookup.

2. Purity quoted without identity confirmed

A COA that reports “99.4% purity by HPLC” and stops there has answered the less important question. HPLC purity describes how much of the injected sample eluted as one dominant peak. It says nothing about whether that peak is the molecule named on the vial. A sequence missing one residue, or with one residue substituted, can chromatograph beautifully and still be 0% of the intended compound.

Identity comes from mass spectrometry: an observed molecular mass matching the theoretical mass for that sequence, within instrument tolerance. On a complete report you should see both, on the same document, for the same lot. Every vendor that later collapsed had one thing in common on this axis - purity was marketed loudly, identity was not evidenced at all.

3. RUO on the label, human-use marketing on the page

FDA’s 2026 letters closed this loophole in explicit language. The Gram Peptides letter states that despite labeling marketing the products for “Research Use Only,” evidence obtained from the website established that the products were intended to be drugs for human use. A product is a drug based on its intended use under section 201(g)(1) of the FD&C Act, and intended use is inferred from the whole context of how a product is presented, under 21 CFR 201.128, not from a disclaimer in the footer.

One detail from those letters is worth internalising, because it is the one vendors most often got wrong:

• The cart is evidence. FDA pointed to bacteriostatic water sold alongside the vials, reasoning that selling the two together demonstrates the vendor intends them to be combined for injection. If you are sourcing diluent for genuine bench work, our bacteriostatic water guide covers what the material actually is.

The practical read for a buyer is inverted from what most people assume. A site plastered with before-and-after photos, dosing charts and testimonials is not more trustworthy for being more helpful. It is a site that has already generated the evidence FDA uses, which makes it more likely to be interrupted mid-order.

4. Payment rails degrading before the site does

This one is observational rather than documented in a government filing, so treat it as a heuristic and not a fact: card processing tends to fail before shipping does. Acquiring banks and payment service providers run their own risk reviews, and they move faster than regulators. A store that accepted Visa and Mastercard last quarter and now offers only cryptocurrency, Zelle, bank transfer or e-check has usually lost an acquirer - and the customer-side consequence is concrete, because those rails have no chargeback mechanism. A card payment that goes nowhere is recoverable. A crypto payment is not.

Watch the checkout page, not the homepage. It changes first, and it changes without an announcement.

What this means for vetting a vendor

The checkable criteria, ordered by how much signal they actually carry:

1. Lab-side COA verification exists. You can enter an accession, task or report number on the laboratory’s own domain and see the report. If the only path to the document is through the vendor, score zero here regardless of how good the PDF looks.
2. Identity and purity both appear on the same report. Mass spec confirming the molecular mass, plus HPLC purity, plus the lot the report belongs to. Purity alone is half an answer.
3. The report is recent and names the vendor as the client. A report dated 2023, or naming a company you have never heard of, is a borrowed document.
4. Coverage is stated honestly, SKU by SKU. A vendor with third-party reports on four products and none on the other six should say so. The dishonest version is a “COAs available” banner that implies catalog-wide testing.
5. RUO discipline holds across the whole site. No dosing guidance, no human-use claims, no testimonials, no protocols. This protects the vendor’s continuity, which is the thing your order actually depends on.
6. Payment rails are conventional. Cards present, crypto optional rather than mandatory.
7. Jurisdiction is legible. A verifiable US shipping origin is a fact about legal exposure and transit time. It is not a fact about product quality, and any page that presents it as one is padding.

Work through those seven against any store using our vendor transparency scorecard, the longer-form US vendor vetting guide, and the red flags catalog. Before you compare prices, normalise them with the cost-per-mg calculator - the collapsed vendors were, almost without exception, the cheapest per milligram in their category right up until the day they weren’t.

One regulatory note for context, because it is being widely misreported. On April 15, 2026 FDA announced the removal of twelve peptide substances from Category 2 of the 503A interim bulks policy, effective roughly a week later, on the basis that the nominations had been withdrawn. Removal from Category 2 is not the same as placement on the 503A bulks list, and it authorizes nothing. A Federal Register notice the following day scheduled a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to consider whether BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon belong on that list, with a further meeting before the end of February 2027. GHK-Cu was moved out of Category 1 pending the same review. None of this alters the status of research-use-only material sold online, and any vendor citing it as evidence that its catalog is now “approved” has told you something useful about itself.

How Pepora scores

Against criterion 1, Pepora clears it on a defined subset. Four products have third-party certificates from Freedom Diagnostics, three of which are listed below, a US laboratory running HPLC with UV detection coupled with mass spectrometry, with each report retrievable by search code at FreedomDiagnosticsTesting.com rather than only from Pepora’s own server:

Product	Reported purity	Accession
GHK-Cu	99.98%	Pepo2603130126
Tesamorelin	99.348%	Pepo2603130125
TB-500 (thymosin beta-4)	99.699%	Pepo2603130123

Because those reports include mass spectrometry alongside HPLC, they answer the identity question as well as the purity question - criterion 2, on the SKUs listed above.

The caveat is the important part, and it is a real limitation rather than a rhetorical one. The rest of the catalog does not have a published Freedom Diagnostics report. BPC-157, Epitalon, Thymosin Alpha-1, ARA-290 and the KLOW, Glow and Wolverine blends are sold without one, and no reader should infer catalog-wide third-party testing from four verified SKUs. Four is better than zero and considerably better than an unverifiable PDF, but it is four.

On criterion 7, Pepora ships from the US, which is a jurisdictional and logistics fact, not a quality claim. On criterion 5, the site holds RUO framing. And the honest closing point on all of it: every vendor in the table above was operating normally at some point too. A vendor is not safe because it is currently alive. It is checkable, or it isn’t - and if this article ages badly for any store named in it, the checks are what survive.

The disclosed pick

FAQ

Which peptide vendors have shut down in 2025 and 2026? Two different things get blurred together here, so separate them. Documented closures are few: Peptide Sciences and Amino Asylum both went dark, and neither has a public enforcement document behind it, so the cause is unconfirmed. FDA warning letters are far more numerous, but a warning letter is an advisory action, not a closure - most recipients were still trading afterwards. The documented enforcement record runs as follows. Criminal: Paradigm Peptides, whose owner Matthew Kawa and co-defendant Jennifer Stechkober pleaded guilty in December 2025 in the Northern District of Indiana (case 3:25-cr-00091) to charges involving unapproved new drugs, after investigators found products sold as SARMs actually contained testosterone. Regulatory: a long and still-growing list of FDA warning letters, including USApeptide.com (Feb 2025), PureRawz (Sept 2025), Pinnacle Peptides (Dec 2025), and seven sellers posted on the same day in April 2026, five research-chemical sites (Pink Pony Peptides, Mile High Compounds, Prime Sciences, Gram Peptides, PekCura Labs) and two eBay stores (FormPour, and Guangzhou Huli Technology Co., Ltd. dba Fantasy Face). Other closures, including Peptide Sciences and Amino Asylum, were widely reported in the community but are not backed by an equivalent public enforcement document, so treat the reported cause as unconfirmed.

Why did Peptide Sciences shut down? Peptide Sciences posted a voluntary closure notice in March 2026 and gave no public explanation. Every published theory - enforcement pressure, payment processing, quality findings - is inference, not a documented cause, and no FDA warning letter or DOJ filing naming the company has surfaced publicly. The honest answer is that a vendor can be operating normally on Monday and gone on Friday without ever telling you why, which is exactly why the pre-purchase checks matter more than the post-mortem.

What happened to Paradigm Peptides? The US Attorney’s Office for the Northern District of Indiana charged Matthew Kawa, owner of Paradigm Peptides (Paradigm R.E. LLC), which shipped peptides, hCG and SARMs from Michigan City, Indiana to thousands of customers nationwide. Investigators determined that many products advertised and labeled as SARMs in fact contained testosterone, a controlled substance, and that the SARM, hCG and peptide products were unapproved new drugs. Kawa pleaded guilty to two counts of introducing unapproved new drugs into interstate commerce in December 2025. DOJ’s victim notice covers purchases between April 2019 and March 2024. Sentencing is currently set for July 30, 2026 before Judge Cristal C. Brisco - check the DOJ case page for the current date.

Does a “research use only” label protect a peptide vendor from the FDA? No, and the 2026 warning letters say so directly. FDA’s Gram Peptides letter states that despite labeling marketing the products for “Research Use Only,” evidence obtained from the website established the products were intended to be drugs for human use. A product is a drug based on its intended use under section 201(g)(1) of the FD&C Act, and 21 CFR 201.128 infers that intended use from context - marketing copy, dosing talk, testimonials, and what else is in the cart. In several letters FDA specifically pointed to bacteriostatic water being sold alongside the vials as evidence of intended injection.

What is the single most predictive red flag before a vendor disappears? A COA that cannot be verified at the laboratory rather than at the vendor. A PDF hosted on the vendor’s own server proves nothing: it can be borrowed from another client, stale by two years, or fabricated outright. A real third-party report carries an accession or task number you can independently look up on the lab’s own site - Janoshik publishes reports at public.janoshik.com, Freedom Diagnostics supports accession lookup at its own domain. Vendors that never expose a lookup are the ones with the least to lose by vanishing.

Did the FDA make peptides legal in 2026? Not in the way the headlines implied. On April 15, 2026 FDA announced the removal of twelve peptide substances from Category 2 of the 503A interim bulks policy, effective roughly April 22, because the nominations had been withdrawn. Removal from Category 2 does not place a substance on the 503A bulks list and does not authorize compounding. FDA published a Federal Register notice on April 16, 2026 scheduling a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to consider whether BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon should be added to the list, with a further meeting before the end of February 2027. Until that concludes, these substances sit in a gray zone, and none of it changes the status of research-use-only material sold online.

References

1. US Department of Justice, US Attorney’s Office, Northern District of Indiana. United States v. Matthew Kawa (victim notice). https://www.justice.gov/usao-ndin/united-states-v-matthew-kawa
2. US Department of Justice, Northern District of Indiana. US v. Matthew Kawa, et al. (case page). https://www.justice.gov/usao-ndin/case/us-v-matthew-kawa-et-al
3. United States of America v. Kawa et al., No. 3:25-cr-00091, US District Court for the Northern District of Indiana (docket). https://www.pacermonitor.com/public/case/60843442/United_States_of_America_v_Kawa_et_al
4. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017;318(20):2004-2010. PMID 29183075. https://pubmed.ncbi.nlm.nih.gov/29183075/
5. US FDA. Warning Letter, Prime Vitality Inc. dba Prime Peptides, MARCS-CMS 695156, December 10, 2024. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-vitality-inc-dba-prime-peptides-695156-12102024
6. US FDA. Warning Letter, Summit Research Peptides, MARCS-CMS 695607, December 10, 2024. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024
7. US FDA. Warning Letter, USApeptide.com, MARCS-CMS 696885, February 26, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025
8. US FDA. Warning Letter, PureRawz, MARCS-CMS 715218, September 8, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purerawz-715218-09082025
9. US FDA. Warning Letter, Pinnacle Professional Research dba Pinnacle Peptides, MARCS-CMS 719337, December 12, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pinnacle-professional-research-dba-pinnacle-peptides-719337-12122025
10. US FDA. Warning Letter, Lovega LLC dba Pink Pony Peptides, MARCS-CMS 721088, March 31, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovega-llc-dba-pink-pony-peptides-721088-03312026
11. US FDA. Warning Letter, Mile High Compounds LLC, MARCS-CMS 721600, March 31, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mile-high-compounds-llc-721600-03312026
12. US FDA. Warning Letter, Gram Peptides, MARCS-CMS 721806, March 31, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
13. US FDA. Warning Letter, Wholesale Peptide, MARCS-CMS 729447, June 17, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wholesale-peptide-729447-06172026
14. US FDA. Warning Letter, PekCura Labs, MARCS-CMS 721709, March 31, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pekcura-labs-721709-03312026
15. US FDA. Warning Letter, Prime Sciences, MARCS-CMS 721805, March 31, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026
16. US FDA. Warning Letter, FormPour (eBay store), MARCS-CMS 722215, March 31, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/formpour-722215-03312026
17. US FDA. Warning Letter, Guangzhou Huli Technology Co., Ltd. dba Fantasy Face, MARCS-CMS 722228, March 31, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangzhou-huli-technology-co-ltd-dba-fantasy-face-722228-03312026
18. US FDA. Warning Letters (searchable database; filter on “peptide” to refresh this list). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
19. US FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (press announcement). https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
20. Wilson Sonsini Goodrich & Rosati. FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers. https://www.wsgr.com/en/insights/fda-sends-warning-letters-to-more-than-50-glp-1-compounders-and-manufacturers.html
21. Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. 2026-07361, April 16, 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
22. Orrick. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to the 503A Bulk Drug Substances List, April 2026. https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings
23. US FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
24. Janoshik Analytical. Public test report index and verification. https://public.janoshik.com/
25. Freedom Diagnostics. Third-party analytical testing and accession lookup. https://freedomdiagnosticstesting.com/

coaindex is a Pepora affiliate (peporalabs.com) and earns a commission on purchases made with the code above. This is affiliate education, not journalism, and it ranks vendors on checkable, independently verifiable third-party-COA criteria. Research use only. Not for human or veterinary use, and nothing here is medical advice.